Osimertinib Impurity 28

Request For Quotation
Osimertinib Impurity 28 Suppliers list
Company Name: Daicel Chiral Technologies (China)CO.,LTD  
Tel: 021-50460086-9 15921403865
Email: han_yajun@dctc.daicel.com
Company Name: Artis Biotech Co. Ltd.  
Tel: 18108108965 18108108965
Email: sales@artisbio.com
Company Name: Shanghai Changyan Chem & Tech Co., Ltd.  
Tel: 021-20242659 18930833303
Email: sales@changyanchem.cn
Company Name: BOC Sciences  
Tel: 16314854226; +8616314854226
Email: inquiry@bocsci.com
Company Name: Nanjing Shizhou Biology Technology Co.,Ltd  
Tel: 025-025-85560043 17301488900
Email: info@synzest.com

Osimertinib Impurity 28 manufacturers

  • Osimertinib-D6
  • Osimertinib-D6 pictures
  • $689.00
  • 2026-07-27
  • CAS:1638281-44-3
  • Purity:
  • Supply Ability: 10g
Osimertinib Impurity 28 Basic information
Product Name:Osimertinib Impurity 28
Synonyms:Osimertinib Impurity 28;2H6]-Osimertinib;N-[2-({2-[di(2H?)methylamino]ethyl}(methyl)amino)-4-methoxy-5-{[4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl]amino}phenyl]prop-2-enamide;D6-Osimertinib
CAS:1638281-44-3
MF:C28H33N7O2
MW:499.62
EINECS:
Product Categories:
Mol File:1638281-44-3.mol
Osimertinib Impurity 28 Structure
Osimertinib Impurity 28 Chemical Properties
form Solid
color White to light yellow
Safety Information
MSDS Information
Osimertinib Impurity 28 Usage And Synthesis
UsesOsimertinib-d6 is a deuterium labeled osimertinib. Osimertinib is a covalent, orally active, irreversible, and mutant-selective EGFR inhibitor with an apparent IC50 of 12 nM against L858R and 1 nM against L858R/T790M. Osimertinib overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer[1].
in vivo

Osimertinib (0.1-25 mg/kg; p.o.; daily for 14 day) induces significant dose-dependent regression in both PC-9 (ex19del) and H1975 (L858R/T790M) tumor xenograft models[1].

Animal Model:PC-9 (ex19del) and H1975 (L858R/T790M) tumor xenograft models[1]
Dosage:0.1-10 mg/kg (PC-9 xenograft models); 0.5- 25 mg/kg (H1975 xenograft models)
Administration:p.o.; daily for 14 day
Result:Induced significant dose-dependent regression in both PC-9 (ex19del) and H1975 (L858R/T790M) tumor xenograft models.
References[1] Cross DA, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014 Sep;4(9):1046-61. DOI:10.1158/2159-8290.CD-14-0337
[2] [2]Hirano T, et al. Pharmacological and Structural Characterizations of Naquotinib, a Novel Third-Generation EGFR Tyrosine Kinase Inhibitor, in EGFR-Mutated Non-Small Cell Lung Cancer. Mol Cancer Ther. 2018 Apr;17(4):740-750. DOI:10.1158/1535-7163.MCT-17-1033
Osimertinib Impurity 28 Preparation Products And Raw materials
Tag:Osimertinib Impurity 28(1638281-44-3) Related Product Information
1,4-BenzenediaMine, N1-[2-(diMethylaMino)ethyl]-5-Methoxy-N1-Methyl-N4-[4-(1-Methyl-1H-indol-3-yl)-2-pyriMidinyl]-2-nitro- Osimertinib mesylate Osimertinib-13CD3 1,2,4-Benzenetriamine, 5-methoxy-N1,N1-dimethyl-N4-[4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]- Osimertinib Impurity M N-(2-(dimethylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide 4-fluoro-2-methoxy-3-nitrobenzenamine AZ 7550 1,4-Benzenediamine, 5-methoxy-N1,N1-dimethyl-N4-[4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]-2-nitro-